


Specialized FISH and cytogenetics services supporting therapeutics development

NeoGenomics provides reliable, high performance FISH and cytogenetics services to empower biopharma partners. Whether you need validated assays or a customized approach, our scientific team supports every phase of development, from assay design and validation to troubleshooting and sample processing across a broad range of hematologic and solid tumor indications.



Identification of HER2 amplification in breast cancer by FISH

Validated FISH assays and panels

ALL
BCR/ABL1 t(9;22)
CDKN2A/CEN9
Cen4/Cen17
Cen6/Cen10
CRFL2 (Xp/Yp)
EPOR (19p13.2)
ETV6/RUNX1 t(12;21)
IGH (14q32)
JAK2 (9p24)
KMT2A/MLL (11q23)
MYC (8q24)
PBX1/TCF3 t(1;19)
PDGFRB (5q33)
AML/MDS
20q12/20qter/8cen
Chromosome 19 (ZNF443/GLTSCR1/2)
Chromosome 5 (hTERT,EGR1,RPS14)
Chromosome 7 (Cen7,D7S2926,D7S2460)
DEK/NUP214 t(6;9)
ETV6 (12p13)
inv(16) CBFβ
KMT2A/MLL (11q23)
MECOM (3q26.2)
NUP98 (11p15.4)
PML/RARA t(15;17)
RARA Break-Apart
RUNX1T1/RUNX1 t(8;21)
TP53/NF1

MPN/Eosinophilia
16q (CBFB)
4q (FIP1L1/CHIC2/PDGFRα)
5q (PDGFRβ)
8p (FGFR1)
Brain cancer
BRAF (7q34)
1p/19q Deletion
Plasma cell myeloma
13q (DLEU/LAMP)
1pq (CDKN2C/CKS1B)
5p15/9q22/15q22 (Hyperdiploidy)
CCND1 (BCL1)/IgH t(11,14)
FGFR3/IgH t(4;14)
IGH (14q32)
IgH/MAF t(14;16)
IgH/MAFB t(14;20)
TP53/NF1
CLL
12/13 (DLEU/LAMP/12cen)
6q (SEC63/MYB)
t(11;14) MYEOV(CCND1)/IGH DF
TP53/ATM
Vysis CLL Panel (TP53, ATM, 13q & 12cen), IVD

Additional validation may be required for certain assays, depending on their intended use. Availability is subject to change. For a current listing, please contact a NeoGenomics representative.

Validated FISH assays and panels

Lymphoma
11q Aberration in NHL
1p36 Deletion
ALK (2p23)
BCL2 (18q21)
BCL6/MYC t(3;8)
BIRC3 (API2)/MALT1 t(11,18)
BL6 (3q27)
CCND1 (BCL1)/IgH t(11,14)
DUSP22-IRF4 (6p25.3)
IGH (14q32)
IgH/BCL2 t(14;18)
IGK/MYC t(2;8)
IGL/MYC t(8;22)
MALT1 (18q21)
MYC (8q24)
MYC/IgH/Cen 8 t(8;14)
TBL1XR1/TP63 t(3;3)
TP63 (3q28)
TP63 Rearrangement
Lung cancer
ALK for NSCLC, IVD
ALK (2p23)
ROS1 (6q22)
Bladder cancer
Cen3/Cen7/Cen17,9p (aneuploidy, p16 deletion)
T-Cell leukemia
TCL1

Various solid tumors
CDKN2A/B (p16)
DDIT3 (CHOP)
EGFR Amplification
EWSR1 (22q12)
FGFR2 Rearrangement
HER2 (HER2 & cen17) Breast and Gastric Cancer, IVD
HER2, across diverse indications
MDM2
Melanoma NeoSITE
MET Amplification
MYC Amplification
MYCN Amplification
NTRK 1, 2, 3
PDGFRA Amplification
PDGFRA Rearrangement
PDGFRB Rearrangement
PTEN Deletion
RET (10q11.2)
SS18 (SYT)
TFE3 Rearrangement
USP6 Rearrangement

Cytogenetics karyotyping

Oncology chromosome analysis
Lymphoid
Myeloid
Plasma cell

Additional validation may be required for certain assays, depending on their intended use. Availability is subject to change. For a current listing, please contact a NeoGenomics representative.

To learn more about **NeoGenomics Pharma Services**, visit us online at [NeoGenomics.com/Partners](https://www.NeoGenomics.com/Partners), call us at 866.776.5907, option 3, or email us at ContactPharma@NeoGenomics.com.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and oncology data solutions. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service, sample-processing laboratory in Cambridge, England, United Kingdom. ©2026 NeoGenomics Laboratories, Inc. All rights reserved.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phn: 866.776.5907
Fax: 239.690.4237

[NeoGenomics.com](https://www.NeoGenomics.com)
All trademarks are the property of their respective owners.
CORP-MRKT-0378 01.26